Paper32192578
COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P and 6 others. Lancet, 2020. Cited by 6,656 papers, by iCite.
Cite this record
ConductScience Library. COVID-19: consider cytokine storm syndromes and immunosuppression. Papers, record 32192578. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192578
- Disease
- COVID-19540 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records4
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases4
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Betacoronavirus | Major topic |
| Coronavirus Infections | Major topic |
| Cytokines | Major topic |
| Immunosuppression Therapy | Major topic |
| Inflammation | Major topic |
| Pneumonia, Viral | Major topic |
| Antirheumatic Agents | |
| COVID-19 | |
| Humans | |
| Immunization, Passive | |
| Immunoglobulins, Intravenous | |
| Immunosuppressive Agents | |
| Pandemics | |
| SARS-CoV-2 | |
| Steroids | |
| COVID-19 Drug Treatment | |
| COVID-19 Serotherapy |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed |
Source PubMed
Trials45
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04328480 | The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. | Results | ClinicalTrials.gov | |
| NCT04339634 | Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy | Background | ClinicalTrials.gov | |
| NCT04340921 | The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury | Background | ClinicalTrials.gov | |
| NCT04343755 | Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection | Background | ClinicalTrials.gov | |
| NCT04345679 | Anti COVID-19 Convalescent Plasma Therapy | Background | ClinicalTrials.gov | |
| NCT04352803 | Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | Background | ClinicalTrials.gov | |
| NCT04353674 | Modulation of Hyperinflammation in COVID-19 | Results | ClinicalTrials.gov | |
| NCT04358926 | Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19) | Background | ClinicalTrials.gov | |
| NCT04361526 | Pilot Study on Cytokine Filtration in COVID-19 ARDS | Background | ClinicalTrials.gov | |
| NCT04366232 | Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation | Results | ClinicalTrials.gov | |
| NCT04374149 | Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS | Background | ClinicalTrials.gov | |
| NCT04377503 | Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 | Background | ClinicalTrials.gov | |
| NCT04379037 | Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients | Background | ClinicalTrials.gov | |
| NCT04400929 | Using GM-CSF as a Host Directed Therapeutic Against COVID-19 | Background | ClinicalTrials.gov | |
| NCT04407182 | Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 | Background | ClinicalTrials.gov | |
| NCT04414059 | Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients | Background | ClinicalTrials.gov | |
| NCT04420260 | Primary Prevention of Infection by COVID-19 in Workers | Background | ClinicalTrials.gov | |
| NCT04438629 | Evaluation of Immune Response in COVID-19 Patients | Background | ClinicalTrials.gov | |
| NCT04454372 | Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) | Results | ClinicalTrials.gov | |
| NCT04456413 | Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection | Background | ClinicalTrials.gov |
Comments and corrections7
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Associated dataset | 34756322 | Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia. | https://conductscience.org/library/papers/34756322 | PubMed |
| Comment in | 32220278 | Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? | https://conductscience.org/library/papers/32220278 | PubMed |
| Comment in | 32238976 | Cytokine storms in COVID-19 cases? | https://conductscience.org/library/papers/32238976 | PubMed |
| Comment in | 32378064 | Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms. | https://conductscience.org/library/papers/32378064 | PubMed |
| Comment in | 32423585 | Is the HScore useful in COVID-19? | https://conductscience.org/library/papers/32423585 | PubMed |
| Comment in | 32631836 | Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? | https://conductscience.org/library/papers/32631836 | PubMed |
| Comment in | 32668194 | Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. | https://conductscience.org/library/papers/32668194 | PubMed |
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32032529 | Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. | Lancet | 2020 | https://conductscience.org/library/papers/32032529 | PubMed |
| 2 | 24290661 | Adult haemophagocytic syndrome. | Lancet | 2014 | https://conductscience.org/library/papers/24290661 | PubMed |
| 3 | 30766533 | Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. | Front Immunol | 2019 | https://conductscience.org/library/papers/30766533 | PubMed |
| 4 | 32043983 | Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. | Lancet | 2020 | https://conductscience.org/library/papers/32043983 | PubMed |
| 5 | 24782338 | Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. | Arthritis Rheumatol | 2014 | https://conductscience.org/library/papers/24782338 | PubMed |
| 6 | 26836913 | Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. | Chest | 2016 | https://conductscience.org/library/papers/26836913 | PubMed |
| 7 | 32125452 | Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. | Intensive Care Med | 2020 | https://conductscience.org/library/papers/32125452 | PubMed |
| 8 | 31986264 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. | Lancet | 2020 | https://conductscience.org/library/papers/31986264 | PubMed |
| 9 | 26584195 | Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. | Crit Care Med | 2016 | https://conductscience.org/library/papers/26584195 | PubMed |
Cited by5,536
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6,656 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42975773 | In vitro antioxidant, anti-inflammatory, antifungal, and anti-HCoV-229E activities of Jatropha integerrima leaf and stem bark extract and in vivo evaluation of its intravenous SNEDDS in a mouse model. | Daru | 2026 | https://conductscience.org/library/papers/42975773 | PubMed |
| 42931232 | Lethal Viral Sepsis/Septic Shock in Getah Virus-Infected Ifnar1-/- Mice. | Pathogens | 2026 | https://conductscience.org/library/papers/42931232 | PubMed |
| 42930509 | Clinical Outcomes and Hospital Resource Utilization Among Patients with Sepsis and COVID-19 Infection: Insights from the United States National Inpatient Sample Analysis, 2020-2022. | Infect Dis Rep | 2026 | https://conductscience.org/library/papers/42930509 | PubMed |
| 42903466 | SARS-CoV-2: Possible role in children with acute hepatitis of unknown origin. | Hlife | 2023 | https://conductscience.org/library/papers/42903466 | PubMed |
| 42872078 | Exploring the Link Between SARS-CoV-2 RT-PCR Cycle Threshold, Clinical Characteristics, and Laboratory Results in Hospitalized COVID-19 Patients With Neurological and Autoimmune Conditions. | Med J Islam Repub Iran | 2025 | https://conductscience.org/library/papers/42872078 | PubMed |
| 42840777 | Triptolide-loaded MSC membrane nanoparticles with enhanced pulmonary accumulation for the treatment of acute lung injury: from network pharmacology to experimental validation. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/42840777 | PubMed |
| 42837035 | Generation of DFNA5-deficient chickens reveals a species-specific role of pyroptosis in avian antiviral immunity. | Transgenic Res | 2026 | https://conductscience.org/library/papers/42837035 | PubMed |
| 42811300 | Hyperinflammatory nutritional index as an exploratory combined inflammatory and nutritional marker: associations with cytokines and β2-microglobulin in COVID-19. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42811300 | PubMed |
| 42796098 | Safety and Changes in Health-Related Quality of Life After Epidural Oxygen Injection for Long COVID/Post-COVID Syndrome: A Multicenter Retrospective Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42796098 | PubMed |
| 42767748 | Defining the preadmission factors that modify risk of acute complications, survival and long-term recovery from COVID-19: prospective, longitudinal, multisite, cohort study based in England. | BMJ Open | 2026 | https://conductscience.org/library/papers/42767748 | PubMed |
| 42757067 | Glutathione Peroxidase (GPx) and Glutathione Reductase Gene Expression as Key Factors in the Glutathione System, in Oxidative Stress Pathways in Patients with COVID-19. | Tanaffos | 2025 | https://conductscience.org/library/papers/42757067 | PubMed |
| 42756421 | Adaptive bandwidth of immunity: a systems-level framework for understanding immune regulation across time. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756421 | PubMed |
| 42741025 | Sex and age are associated with host immune responses and multi-organ dysfunction in hospitalized patients with COVID-19. | Front Public Health | 2026 | https://conductscience.org/library/papers/42741025 | PubMed |
| 42707763 | Repair and regeneration across the lifespan: an ontogenetic perspective. | Front Aging | 2026 | https://conductscience.org/library/papers/42707763 | PubMed |
| 42685097 | Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. | PLoS One | 2026 | https://conductscience.org/library/papers/42685097 | PubMed |
| 42655643 | The Environmental Polycyclic Aromatic Hydrocarbon (PAH) Benzo[a]pyrene (BP) Alters SARS-CoV-2 Pathogenesis in a Mouse Model of Disease. | Viruses | 2026 | https://conductscience.org/library/papers/42655643 | PubMed |
| 42650274 | Phytochemical Profiling and Proteomic Insights into the Anti-Inflammatory Effects of Jing Guan Fang in LPS-Stimulated Macrophages. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42650274 | PubMed |
| 42589551 | Neurodegenerative and Cognitive Consequences of Long COVID. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589551 | PubMed |
| 42553313 | Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42553313 | PubMed |
| 42553204 | Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications. | Front Immunol | 2026 | https://conductscience.org/library/papers/42553204 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCL2 | 6347 | PubTator's text mining | https://conductscience.org/library/genes/6347 | NCBI Gene |
| CCR1 | 1230 | PubTator's text mining | https://conductscience.org/library/genes/1230 | NCBI Gene |
| CSF3 | 1440 | PubTator's text mining | https://conductscience.org/library/genes/1440 | NCBI Gene |
| CXCL10 | 3627 | PubTator's text mining | https://conductscience.org/library/genes/3627 | NCBI Gene |
| FGB | 2244 | PubTator's text mining | https://conductscience.org/library/genes/2244 | NCBI Gene |
| IL1A | 3552 | PubTator's text mining | https://conductscience.org/library/genes/3552 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| IL7 | 3574 | PubTator's text mining | https://conductscience.org/library/genes/3574 | NCBI Gene |
Drugs6
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| COLCHICINE | CHEMBL107 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL107 | ChEMBL |
| ANAKINRA | CHEMBL1201570 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201570 | ChEMBL |
| CYCLOSPORINE | CHEMBL160 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL160 | ChEMBL |
| RUXOLITINIB | CHEMBL1789941 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1789941 | ChEMBL |
| CLAZAKIZUMAB | CHEMBL2108589 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL2108589 | ChEMBL |
| ASPIRIN | CHEMBL25 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL25 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32192578
GET https://conductscience.org/api/papers/v1/32192578/trials?page=2